Sign In
Buy AGEN
$3.07
+0.0300 (+0.99%)
At Close: Jun 23, 2026
Agenus and Bristol Myers Squibb Announce Exclusive Global License for Agenus' Anti-TIGIT Bispecific Antibody Program
07:30am, Tuesday, 18'th May 2021
Agenus to receive a $200 million upfront payment and up to $1.36 billion in milestone payments Agenus to receive a $200 million upfront payment and up to $1.36 billion in milestone payments
7 Small-Cap Biotech Stocks to Watch for Upcoming Catalysts
03:45pm, Wednesday, 12'th May 2021
Small-cap stocks in the biotech space have been in a slump, but these seven companies could see big moves just around the corner. The post 7 Small-Cap Biotech Stocks to Watch for Upcoming Catalysts ap
Why Agenus Stock Tumbled Today
03:55pm, Thursday, 06'th May 2021
The company announced mixed Q1 results on a day when many biotech stocks were sinking.
Agenus ' (AGEN) CEO Garo Armen on Q1 2021 Results - Earnings Call Transcript
12:02pm, Thursday, 06'th May 2021
Agenus ' (AGEN) CEO Garo Armen on Q1 2021 Results - Earnings Call Transcript
Agenus Corporate Update and First Quarter 2021 Financial Report
07:45am, Thursday, 06'th May 2021
LEXINGTON, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines d
Agenus to Present at the 2021 ASCO Annual Meeting
05:30pm, Wednesday, 28'th Apr 2021
LEXINGTON, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines desi
Agenus to Provide Corporate Update and First Quarter 2021 Financial Report
04:05pm, Thursday, 22'nd Apr 2021
Conference Call on Thursday, May 6, 2021 at 8:30 a.m. ET Conference Call on Thursday, May 6, 2021 at 8:30 a.m. ET
Agenus 1181 New Cancer Response Data Adds To Conviction
12:44pm, Wednesday, 14'th Apr 2021
AGEN1181 is an enhanced CTLA-4 inhibitor, a cancer therapy. Updated preliminary Phase 1 trial results were presented at AACR.
Agenus Doses First Cancer Patient with iNKT Cell Therapy
08:30am, Wednesday, 14'th Apr 2021
LEXINGTON, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines
New Clinical Responses for AGEN1181 Presented at AACR
08:35am, Saturday, 10'th Apr 2021
LEXINGTON, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines desi
Agenus A Buy On Coming 2021 Data, FDA Filings
10:51pm, Monday, 15'th Mar 2021
Agenus A Buy On Coming 2021 Data, FDA Filings
Agenus Inc. (AGEN) CEO Garo Armen on Q4 2020 Results - Earnings Call Transcript
01:37pm, Monday, 15'th Mar 2021
Agenus Inc. (AGEN) CEO Garo Armen on Q4 2020 Results - Earnings Call Transcript
Agenus (AGEN) Reports Q4 Loss, Tops Revenue Estimates
10:13am, Monday, 15'th Mar 2021
Agenus (AGEN) delivered earnings and revenue surprises of 9.09% and 92.69%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Agenus Corporate Update and Fourth Quarter & Full Year 2020 Financial Report
07:45am, Monday, 15'th Mar 2021
LEXINGTON, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccin
Agenus to Present New Clinical Data on AGEN1181 at AACR 2021
04:33pm, Wednesday, 10'th Mar 2021
LEXINGTON, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines
